For a stock that has shed roughly 36% of its value over the past year, $30 has become a natural psychological milestone. The Campbell's Company (CPB) — the packaged-food giant formerly known as Campbell Soup Company — spent much of the second half of 2025 trading in the $30–$34 range before a prolonged slide carried it toward its 52-week low of $19.56. A move back to $30 would represent a recovery to a level many shareholders remember as "normal," making it one of the most frequently discussed price targets among retail investors.
Founded in 1869 and headquartered in Camden, New Jersey, The Campbell's Company operates through two segments: Meals & Beverages (soups, broths, Prego and Rao's sauces, Pace, and V8) and Snacks (Pepperidge Farm, Goldfish, Snyder's of Hanover, Lance, Cape Cod, and Kettle Brand). The company renamed itself in late 2024 to reflect its broader snacking and meals portfolio and installed a new chief executive in early 2025.
Fundamentally, the business is under pressure. Revenue, which reached roughly $10.25 billion in fiscal 2025, is forecast to decline around 5% in fiscal 2026, while earnings per share are expected to fall by more than a quarter. The stock's price-to-earnings (P/E) ratio of about 11x — the price investors pay per dollar of earnings — reflects the market's skepticism about near-term growth. On the positive side, CPB carries a dividend yield near 6.8%, a level that has historically attracted income-oriented investors and helped cushion downside.
Several factors could support a climb toward $30. First, the valuation itself is unusually low for a company with this much brand equity; if management can stabilize margins, even a modest re-rating toward historical averages would move the shares meaningfully. Second, the premium Rao's brand acquired in 2024 remains a growth avenue within the meals portfolio. Third, the roughly 7% dividend yield gives value and income investors a reason to hold through volatility, potentially limiting how far the stock falls. Finally, consumer staples are traditionally viewed as defensive; a rotation back into defensive names during broader market uncertainty could lift the entire sector, CPB included.
The obstacles are substantial. The company is contending with declining organic sales, input-cost inflation, competitive pressure from private-label products, and softness in its snacks business. Net income margins have compressed to the low single digits, and analysts expect earnings to decline further in the coming fiscal year. The weight-loss-drug trend has also pressured volumes across the packaged-food industry as consumers shift their purchasing habits. Against this backdrop, the market has been unwilling to reward the stock with a higher multiple, keeping it anchored near multi-year lows.
Wall Street's view is notably cautious. Across major data providers, the consensus rating on CPB sits between "Hold" and "Reduce," with an average 12-month price target roughly in the $20–$23 range — at or slightly below the recent share price. Recent actions illustrate the mood: firms such as CPB analysts at UBS, Bank of America, and Wells Fargo have maintained or reiterated Sell-equivalent ratings, while several hold-rated firms (J.P. Morgan, Stifel, TD Cowen) have lifted targets only modestly to the $21–$22 area. The highest published target sits near $26, still short of $30. A notable outlier reaching $56 exists in some datasets but is far removed from the broader consensus and should be treated with caution.
From a technical analysis perspective, the stock's long-term trend remains downward, but it has stabilized in 2026. Support has repeatedly formed around the $20 round number and the 52-week low of $19.56. On the upside, the shares recently encountered resistance near $24 before pulling back. A sustained break above $24 would open the door to the $26–$27 zone, and only then would $30 become a realistic near-term objective. Each of these levels represents an area where prior supply and demand have repeatedly changed hands.
For traders seeking to monitor whether CPB can build momentum toward higher levels, AI Daily Buy/Sell Signals offers an automated way to stay informed. This product uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to surface new opportunities, monitor existing positions, and identify changing market trends more efficiently than manual screening allows.
Reaching $30 is a plausible long-term scenario but not a near-term probability. The strongest arguments in favor are the depressed valuation, the high dividend yield, and the fact that the shares traded comfortably above $30 less than a year ago. The primary risks are persistent revenue and earnings declines, margin compression, and an analyst community that remains broadly skeptical. For the target to become realistic, investors would likely need to see evidence of stabilizing sales, recovering margins, and a re-acceleration in the snacks segment — catalysts that have yet to materialize. Until then, $30 should be viewed as a recovery milestone rather than an imminent price forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CPB has been closely correlated with KHC. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if CPB jumps, then KHC could also see price increases.
| Ticker / NAME | Correlation To CPB | 1D Price Change % |
|---|---|---|
| CPB | 100% | -2.31% |
| CPB (4 stocks) | 87% Closely correlated | -1.20% |
| Food: Major Diversified (63 stocks) | 1% Poorly correlated | -0.61% |